




## Supplementary Information




(a)



(b)




(c)




(d)


Figure S1:  $^1\text{H}$  NMR spectra of (a) GLH, (b) Sar-LH, (c) GFH and (d) Sar-FH at increasing pH values from 2-11. An arrow has been added to indicate the shifting of peaks over increasing pH values.



(a)



(b)



(c)

Figure S2. 1D selective gradient TOCSY NMR spectra (red) and  $^1\text{H}$  NMR spectra (blue) of GLH at pH 4.5. (a) full spectrum of the irradiated amide-NH peak **d** at 8.246 ppm, (b) full spectrum of the

irradiated amide-NH peak **i** at 8.511 ppm and (c) section of the spectrum of the irradiated amide-NH peak **i** at 8.511 ppm. An arrow has been added to indicate the irradiated amide-N.




Figure S3. The  $^1\text{H}$  NMR spectra (blue) of the ligand GFH and the  $^1\text{H}$  NMR spectra (red) after GFH has been titrated with copper(II) to reach a 5:1 ligand copper(II) ratio at a pH of 4.8 in 90 % water and 10 %  $\text{D}_2\text{O}$ .  $^1\text{H}$  NMR spectra (green) with arrows pointing to the significant broadening of peaks **b** and **b'**, after GFH has been titrated with copper(II).




Figure S4. The  $^1\text{H}$  NMR spectra (blue) of the ligand Sar-FH and the  $^1\text{H}$  NMR spectra (red) after Sar-FH has been titrated with copper(II) to reach a 5:1 ligand copper(II) ratio at a pH of 4.8 in 90 % water

and 10 % D<sub>2</sub>O. <sup>1</sup>H NMR spectra (green).with arrows pointing to the significant broadening of peaks **b** and **b'**, after Sar-FH has been titrated with copper(II)

**Table S1.** Structural assignments of m/z base peaks that were found in the ESI-MS spectrum for Cu-GLH, Cu-Sar-FH and Cu-GFH at pH 5 (positive mode) with a 1:1 ratio and concentration of 1 mM for GLH, Sar-FH and GFH, and 0.7 mM for copper(II) in aqueous solution

| Complex   | m/z    | Assignment  |
|-----------|--------|---|
| Cu-GLH    | 326.24 | (LH+H) <sup>1+</sup>  |
|           | 348.08 | (LH+Na) <sup>1+</sup>   |
|           | 370.06 | (L+2Na) <sup>1+</sup>   |
|           | 371.04 | uncomplexed ligand  |
|           | 387.07 | (MLH <sub>-2</sub> +2H) <sup>1+</sup>                               |
|           |        | (MLH <sub>-1</sub> +H) <sup>1+</sup>                                |
|           | 388.05 | (M'LH <sub>-2</sub> +3H) <sup>1+</sup>                              |
|           |        | (M'LH <sub>-1</sub> +2H) <sup>1+</sup>                              |
| Cu-Sar-FH | 368.03 | (L+Na-benzene ring decomposition) <sup>1+</sup>                     |
|           | 374.12 | (LH+H) <sup>1+</sup>  |
|           | 396.10 | (LH+Na) <sup>1+</sup>   |
|           | 408.00 | (M'LH <sub>-2</sub> +2H-benzene ring decomposition) <sup>1+</sup>   |
|           | 418.22 | (L+2Na) <sup>1+</sup>   |
|           | 430.12 | (M'LH <sub>-2</sub> +H+Na-benzene ring decomposition) <sup>1+</sup> |
|           | 435.02 | (MLH <sub>-2</sub> +2H) <sup>1+</sup>                               |
|           | 436.07 | (M'LH <sub>-2</sub> +3H) <sup>1+</sup>                              |
| Cu-GFH    | 354.94 | (MLH <sub>-2</sub> +H-imidazole) <sup>1+</sup>                      |
|           | 360.19 | (LH+H) <sup>1+</sup>  |
|           | 370.97 | (MLH <sub>-2</sub> +H-imidazole+H <sub>2</sub> O) <sup>1+</sup>     |
|           | 382.10 | (LH+Na) <sup>1+</sup>   |
|           | 404.15 | (L+2Na) <sup>1+</sup>   |
|           | 421.02 | (MLH <sub>-2</sub> +2H) <sup>1+</sup>                               |
|           | 422.07 | (M'LH <sub>-2</sub> +3H) <sup>1+</sup>                              |